Rosenberg Steven A, Sportès Claude, Ahmadzadeh Mojgan, Fry Terry J, Ngo Lien T, Schwarz Susan L, Stetler-Stevenson Maryalice, Morton Kathleen E, Mavroukakis Sharon A, Morre Michel, Buffet Renaud, Mackall Crystal L, Gress Ronald E
Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1201, USA.
J Immunother. 2006 May-Jun;29(3):313-9. doi: 10.1097/01.cji.0000210386.55951.c2.
Lymphopenia is a serious consequence of HIV infection and the administration of cancer chemotherapeutic agents. Although growth factors can be administered to patients to increase circulating neutrophils, there is no effective method to stimulate CD8+ lymphocyte production in humans, in vivo. This report is the first to describe the administration of recombinant interleukin-7 to humans and demonstrates the ability of this cytokine to mediate selective increases in CD4+ and CD8+ lymphocytes along with a decrease in the percentage of CD4+ T-regulatory cells. These studies suggest an important role for interleukin-7 in the treatment of patients with lymphopenia.
淋巴细胞减少是HIV感染和癌症化疗药物给药的严重后果。尽管可以给患者使用生长因子以增加循环中的中性粒细胞，但在人体内，目前尚无有效方法来刺激CD8+淋巴细胞的产生。本报告首次描述了重组白细胞介素-7在人体中的给药情况，并证明了这种细胞因子能够介导CD4+和CD8+淋巴细胞的选择性增加，同时降低CD4+调节性T细胞的百分比。这些研究表明白细胞介素-7在淋巴细胞减少患者的治疗中具有重要作用。
